MetP Pharma's Nose-to-Brain Technology Achieves Superior Peptide Delivery Compared to Blood-Brain Barrier Shuttles
核心洞察
MetP Pharma (搜索)'s intranasal nose-to-brain drug delivery technology demonstrates superior brain targeting efficiency for peptides, achieving brain-to-plasma ratios well above 1 and ID percentage values within the highly successful range for peptides.
The company's nasal semaglutide gel formulation outperforms traditional blood-brain barrier transporter approaches like BrainShuttle (搜索) by enabling direct neural pathway delivery with minimal systemic exposure.
The technology offers significant advantages including non-invasive self-administration, reduced off-target effects, lower development complexity, and avoidance of BBB receptor interference compared to transporter-based systems.
MetP Pharma (搜索) AG has released preclinical data demonstrating that its proprietary nose-to-brain drug delivery technology achieves superior brain targeting efficiency compared to systemic blood-brain barrier transporter approaches, setting new benchmarks for peptide delivery to the central nervous system.
The Swiss pharmaceutical company's intranasal delivery platform leverages direct neural pathways, including olfactory and trigeminal pathways, to achieve high localized brain concentrations while minimizing systemic exposure. This approach fundamentally differs from systemic high-dose strategies that rely on maximizing plasma concentrations.
Breakthrough Performance Metrics
MetP Pharma (搜索)'s previously unreported preclinical data shows its nasal semaglutide gel formulation achieves brain-to-plasma ratios well above 1, time- and dose-dependent brain exposure, and ID percentage values within the highly successful range for peptides. Most approved CNS drugs achieve less than 1 percent injected dose reaching the brain, while for peptides, 1-5 percent ID combined with a brain-to-plasma ratio greater than 1 is considered excellent targeting efficiency.
"These findings provide strong support for therapeutically relevant clinical effects of semaglutide using MetP Pharma (搜索)'s DDT, including appetite suppression and modulation of food reward and addiction diseases," according to the company's announcement.
Competitive Advantages Over BBB Shuttles
The nose-to-brain technology offers several decisive advantages compared to transporter-based approaches like BrainShuttle (搜索) and other receptor-mediated systems:
Non-invasive Administration: While transporter systems require intravenous injection or infusion with medical supervision and clinical infrastructure, MetP Pharma (搜索)'s technology enables easy self-administration suitable for long-term, repeated dosing.
Reduced Systemic Burden: BBB shuttles depend on systemic circulation and high peripheral exposure prior to brain delivery. The transferrin receptor (搜索) (TfR (搜索)), widely expressed in peripheral tissues such as erythrocytes, liver, and muscle, creates risks of off-target uptake and peripheral toxicity observed in some clinical programs.
Lower Development Complexity: Shuttle technologies rely on highly engineered bispecific antibodies or fusion proteins, increasing development complexity, manufacturing costs, and immunogenicity risk. MetP Pharma (搜索)'s formulation-based approach is significantly simpler to develop and more cost-effective to scale.
Safety Profile: Chronic engagement of BBB receptors such as TfR (搜索) raises theoretical concerns around interference with physiological ligand transport and long-term effects on endothelial cells. The nose-to-brain approach completely avoids manipulation of BBB receptors.
Addressing Industry Misconceptions
Dr. Claudia Mattern, Chief Scientific Officer of MetP Pharma (搜索), addressed common misconceptions about nose-to-brain delivery: "It is not possible to calculate the bioavailability for the N2B technology because a comparison with intravenous administration would be methodologically incorrect due to the lack of plasma availability. Asking for IV bioavailability in a nose-to-brain system is like criticising a scalpel for weighing less than a hammer."
The company emphasizes that the absence of plasma exposure is a feature, not a limitation, of effective neural targeting, distinguishing it from approaches that require high systemic exposure.
Strategic Partnership Opportunities
MetP Pharma (搜索) positions its neural targeting technology as a plug-and-play enabling platform for existing peptide portfolios. The company is actively pursuing strategic partnerships to apply the technology across metabolic, neurological, and neuropsychiatric indications.
The market increasingly rewards therapies offering rapid onset, lower doses, improved tolerability, and better patient compliance - areas where MetP Pharma (搜索)'s approach delivers clear advantages according to the company.
MetP Pharma (搜索)'s proprietary technology platform is protected by a strong global intellectual property portfolio until 2037/2039 and has been validated through 67 predominantly peer-reviewed publications from independent research institutions worldwide.